- ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 - - ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline data in the first

SAN FRANCISCO , May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

Webinar to feature presentations from Harold Bays, MD, and Deepak L. Bhatt, MD, MPH, on Wednesday, May 4th at 11:00 a.m. PT/2:00 p.m. ET SAN FRANCISCO , April 26, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH – – ENLIVEN Phase 2b NASH trial on track for topline data in first half of 2023 – – Closed enrollment

SAN FRANCISCO , Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E.

SAN FRANCISCO , Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%) Robust changes on multiple non-invasive liver tests, markers of cardiovascular

New sub-analysis presented at The Liver Meeting ® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients Oral presentation was highlighted by the AASLD Scientific Program Committee as a key presentation in The Liver Meeting ® 2021 SAN FRANCISCO , Nov.

SAN FRANCISCO , Nov. 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte